A website to provide support for people who have or have had any type of cancer, for their caregivers and for their family members.
Results 1 to 4 of 4

Thread: Non-Invasive Transdermal CO2 Delivery

  1. #1
    Newbie New User
    Join Date
    Mar 2017
    Posts
    3

    Non-Invasive Transdermal CO2 Delivery

    Hello-Looking for any available feedback for this approach to managing side effects and maintaining strength during chemo. It increases blood flow without metastatis? Zero safety issues?

    db

  2. #2
    Administrator Top User lisa1962's Avatar
    Join Date
    Jan 2013
    Location
    new york
    Posts
    3,130
    dbjackson:

    I have not heard this ever mentioned in the forum and I suggest you discuss with your doctor. Your previous post was unclear your reason for posting regarding your Mom and not fit enough for chemotherapy. If you can share your reason for being here perhaps others may have some information that may be specific to your situation.

    Lisa

  3. #3
    Super Moderator Top User po18guy's Avatar
    Join Date
    Feb 2012
    Location
    Pacific NW, USA
    Posts
    8,256
    Everything I can locate on the web deals with c02 improving chronic wound healing and with reconstitution of damaged skin. This is definitely a subject that should be discussed with doctor.
    07/08 Age 56 DX 1) Peripheral T-Cell Lymphoma-Not Otherwise Specified. Stage IV-B, >50 ("innumerable") tumors, bone marrow involvement.
    08/08-12/08 Four cycles CHOEP14 + four cycles GND (Cyclofosfamide, Doxorubicin, Vincristine, Etoposide, Prednisone & Gemcitabine, Navelbine, Doxil)
    02/09 2) Relapse.
    03/09-06/13 Clinical trial of Romidepsin > long-term study. NED for 64 twenty-eight day cycles, dose tapered.
    07/13 3) Relapse, 4) Suspected Mutation.
    08/13-02/14 Romidepsin increased, stopped for lack of response. Watch & Wait.
    09/14 Relapse/Progression. Visible cervical nodes appear within 4 days of being checked clear.
    10/06/14 One cycle Belinostat. Discontinued to enter second clinical trial.
    10/25/14 Clinical trial of Alisertib/Failed - Progression.
    01/12/15 Belinostat resumed/Failed - Progression. 02/23/15
    02/24/15 Pralatrexate/Failed - Progression. 04/17/15
    04/15 Genomic profiling reveals mutation into PTCL-NOS + AngioImmunoblastic T-Cell Lymphoma. Stage IV-B a second time. Two dozen tumors + small intestine (Ileum) involvement.
    04/22/15 TREC (Bendamustine, Etoposide, Carboplatin). Full response in two cycles. PET/CT both clear. Third cycle followed.
    06/15-07/15 Transplant preparation (X-rays, spinal taps, BMB, blood test, MUGA scan, lung function, CMV screening, C-Diff testing etc. etc. etc.) Intrathecal Methotrexate during spinal tap.
    BMB reveals 5) 26% blast cells of 20q Deletion Myelodysplastic Syndrome MDS), a bone marrow cancer.
    07/11-12/15 Cyclofosfamide + Fludarabine conditioning regimen.
    07/16/15 Total Body Irradiation.
    07/17/15 Moderate intensity Haploidentical Allogeneic Stem Cell Transplant receiving my son's peripheral blood stem cells.
    07/21-22/15 Triple dose Cyclofosfamide + Mesna, followed by immunosuppressants Tacrolimus and Mycophenolate Mofetil.
    07/23-08/03/15 Marrow producing zero blood cells. Fever. Hospitalized two weeks.
    08/04/15 Engraftment occurs, and blood cells are measureable - released from hospital.
    08/13/15 Day 26 - Marrow is 100% donor cells. Platelets climbing steadily, red cells follow.
    09/21/15 Acute skin Graft versus Host Disease arrives.
    DEXA scan reveals Osteoporosis.
    09/26/-11/03/15 Prednisone to control skin GvHD.
    11/2015 Acute GvHD re-classified to Chronic Graft versus Host Disease.
    05/2016 Tacrolimus stopped. Prednisone from 30-90mg daily tried. Sirolimus begun.
    09/16/16 Three skin punch biopsies.
    11/04/16 GvHD clinical trial of Ofatumumab (Arzerra) + Prednisone + Methylprednisolone begun.
    12/16 Type II Diabetes, Hypertension - both treatment-related.
    05/17 Extracorporeal Photopheresis (ECP) begun in attempt to control chronic Graft-versus-Host-Disease (cGvHD.
    06/17 Trying various antibiotics in a search for tolerable prophylaxis.
    08/17 Bone marrow biopsy reveals the presence of 2% cells with 20q Deletion Myelodysplastic Syndrome, considered to be Minimum Residual Disease. Active surveillance is the course of choice.
    To date: 18 chemotherapeutic drugs in 9 regimens (4 of them at least twice), 5 salvage regimens, 3 clinical trials, 4 post-transplant immuno-suppressant drugs, the equivalent of 1,000 years of background radiation from scanning from 45+ CT series scans and about 24 PET scans. Two lymphoid malignancies plus a myeloid malignancy lend a certain symmetry to the journey.

    Believing in the redemptive value of suffering makes all the difference.

  4. #4
    Newbie New User
    Join Date
    Aug 2017
    Posts
    1
    My mother uses this because she has ESRD. It improves your microcirculation. She's been "lively" since and there's quite an improvement on her skin and general health. She still needs to watch what she eats though.

 

Similar Threads

  1. Nanotechnology Drug Delivery News
    By lancepeace in forum Cancer News
    Replies: 9
    Last Post: 01-26-2015, 08:31 PM
  2. Replies: 10
    Last Post: 05-06-2014, 12:59 PM
  3. basal cell treatments non invasive
    By mick sims in forum Melanoma and Skin Cancer Forum
    Replies: 2
    Last Post: 03-16-2006, 09:24 PM
  4. Replies: 0
    Last Post: 05-23-2005, 04:00 AM
  5. Stage I: Invasive ductal carcinoma
    By Roxi1 in forum Breast Cancer Forum
    Replies: 15
    Last Post: 03-14-2005, 07:23 PM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •